Journal
HEMATOLOGICAL ONCOLOGY
Volume 36, Issue 1, Pages 285-290Publisher
WILEY
DOI: 10.1002/hon.2429
Keywords
intermediate-1 risk; IPSS; MF; myelofibrosis; ruxolitinib
Categories
Funding
- BolognAIL
- RFO
- Thuringian state programme ProExzellenz [RegenerAging - FSU-I-03/14]
Ask authors/readers for more resources
Patients with myelofibrosis at intermediate-1 risk according to the International Prognostic Score System are projected to a relatively long survival; nonetheless, they may carry significant splenomegaly and/or systemic constitutional symptoms that hamper quality of life and require treatment. Since registrative COMFORT studies included only patients at intermediate-2/high International Prognostic Score System risk, safety and efficacy data in intermediate-1 patients are limited. We report on 70 intermediate-1 patients treated with ruxolitinib according to standard clinical practice that were evaluated for response using the 2013 IWG-MRT criteria. At 6months, rates of spleen and symptoms response were 54.7% and 80% in 64 and 65 evaluable patients, respectively. At 3months, ruxolitinib-induced grade 3 anemia and thrombocytopenia occurred in 40.6% and 2.9% of evaluable patients, respectively. Notably, 11 (15.9%) patients experienced at least one infectious event grade 2. Most (82.6%) patients were still on therapy after a median follow-up of 27months. These data support the need for standardized guidelines that may guide the decision to initiate ruxolitinib therapy in this risk category, balancing benefit expectations and potential adverse effects.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available